Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of British Columbia

$27,000.00

Structural and Inflammatory Changes Following Treatment of Cystic Fibrosis with ETI

EF 2025-26

Résumé
Cystic Fibrosis (CF) in the most common genetic disease in Canada, affecting over 4500 people (roughly 1 in 3848 live births). CF is caused by mutations to the CFTR gene, which affects fluid transport around the body and has a particularly negative effect on the lungs. In people with CF, long-lasting inflammation plays a major role in lung damage and loss of lung function over time. In 2021, a medication called Trikafta was approved by Health Canada for use in people with CF. The medication helps the faulty CFTR protein work better, which leads to major health improvements in most, but not all, patients. Following the approval of Trikafta, a multi-centre Canadian study was launched to evaluate the long-term impact that Trikafta has on inflammation in people with CF. The goal of this project is to analyze data generated in the study to try to better understand how people respond to the drug. The analysis will focus on two types of data: 1) computed tomography (CT) scans, which provide detailed images of lung structure 2) Inflammatory markers measured in the blood Both types of data have been collected at baseline and follow-up visits. Machine learning algorithms will be used to find patterns and relationships in how lung structure and inflammation change over time. These patterns may help explain differences in how people respond to treatment. This project is significant because even thought Trikafta has transformed CF care, some people benefit less than others, and the reason remains unclear. This research aims to identify early signs of incomplete response, guide more personalized treatment strategies, and ultimately improve long-term care for people with CF.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573118
Name
Dyce Josh
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Structural and Inflammatory Changes Following Treatment of Cystic Fibrosis with ETI
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Clinical Response; Clustering; Computed Tomography; Cystic Fibrosis; Cytokines; Drug Therapy; Eti; Inflammation; Machine Learning; Trikafta
Abstract
Cystic Fibrosis (CF) in the most common genetic disease in Canada, affecting over 4500 people (roughly 1 in 3848 live births). CF is caused by mutations to the CFTR gene, which affects fluid transport around the body and has a particularly negative effect on the lungs. In people with CF, long-lasting inflammation plays a major role in lung damage and loss of lung function over time. In 2021, a medication called Trikafta was approved by Health Canada for use in people with CF. The medication helps the faulty CFTR protein work better, which leads to major health improvements in most, but not all, patients. Following the approval of Trikafta, a multi-centre Canadian study was launched to evaluate the long-term impact that Trikafta has on inflammation in people with CF. The goal of this project is to analyze data generated in the study to try to better understand how people respond to the drug. The analysis will focus on two types of data: 1) computed tomography (CT) scans, which provide detailed images of lung structure 2) Inflammatory markers measured in the blood Both types of data have been collected at baseline and follow-up visits. Machine learning algorithms will be used to find patterns and relationships in how lung structure and inflammation change over time. These patterns may help explain differences in how people respond to treatment. This project is significant because even thought Trikafta has transformed CF care, some people benefit less than others, and the reason remains unclear. This research aims to identify early signs of incomplete response, guide more personalized treatment strategies, and ultimately improve long-term care for people with CF.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dyce, Josh
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~